NYSE:MED
MEDIFAST INC
A direct-to-consumer health company leveraging proprietary meal replacement systems to drive revenue in the growing clinical nutrition sector.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe the company is pivoting to a more sustainable business model that can restore profitability given its strong operational cash flow and low debt load relative to equity; the brand's dominance in clinical nutrition offers a defensible niche with recurring revenue potential from subscription-based meal plans; current valuations may reflect temporary distress rather than long-term structural failure.
Bear Case
The sharp decline in revenue over five years, combined with widening losses and a growing retained earnings deficit of -$158.3M, presents a severe risk of permanent capital impairment; investors should avoid the stock given the inability to convert operational cash flow into net profit and the aggressive consumption of cash through investing activities; without a clear turnaround strategy or significant external funding, the company faces an existential threat.
About MEDIFAST INC
Medifast Inc. (NYSE: MED) is a leading provider of weight management and wellness solutions, offering proprietary meal plans, supplements, and coaching services primarily through its Optifast brand in the US and international markets.
Analysis
Management Discussion
The company has transitioned from profitability in prior years to significant losses, with 2025 net income dropping to -$18.7M and operating profit at -$14.2M. Despite generating positive cash flow from operations of $6.9M, the firm is facing a substantial working capital outflow of -$51.2M and investing heavily in other assets totaling -$97.9M, while maintaining a healthy cash balance of $89.3M to manage liquidity.
Industry Overview
The clinical nutrition and weight management industry is competitive but fragmented, with opportunities for companies that combine medical-grade products with digital coaching platforms. Market demand remains robust due to rising obesity rates, yet intense competition from low-cost generic alternatives and lifestyle-focused apps pressures margins and accelerates customer churn.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.60B | $1.07B | $602.5M | $385.8M |
| Cost of Revenue | $458.2M | $296.2M | $157.8M | $110.6M |
| Gross Profit | $1.14B | $775.9M | $444.6M | $275.2M |
| Operating Expenses | $955.6M | $649.4M | $441.7M | $289.4M |
| Operating Income | $184.8M | $126.4M | $2.9M | $-14.2M |
| R&D | $4.5M | $4.6M | $4.6M | $4.3M |
| G&A | $955.6M | $649.4M | $441.7M | $289.4M |
| Stock-Based Comp | $11.1M | $8.2M | $7.4M | $7.6M |
| D&A | $11.0M | $13.1M | $12.7M | $14.2M |
| Depreciation | $7.9M | $10.0M | $17.4M | $10.5M |
| Other OpEx | $-4.5M | $-4.6M | $-4.6M | $-4.3M |
| Non-Operating Income | $-747.0K | $2.4M | $909.0K | $8.6M |
| Pre-Tax Income | $184.1M | $128.8M | $3.8M | $-5.6M |
| Income Tax | $40.5M | $29.4M | $1.7M | $13.0M |
| Continuing Ops | $143.6M | $99.4M | $2.1M | $-18.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $143.6M | $99.4M | $2.1M | $-18.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $143.6M | $99.4M | $2.1M | $-18.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $222.8M | $224.0M | $214.4M | $201.7M |
| Cash & Equivalents | $87.7M | $94.4M | $90.9M | $89.3M |
| Marketable Securities | $0 | — | $71.4M | $78.0M |
| Inventory | $118.9M | $54.6M | $42.4M | $20.2M |
| Prepaid Expenses | $16.2M | $10.7M | $9.6M | $9.1M |
| Other Current Assets | $0 | $64.3M | $0 | $5.1M |
| Long-Term Assets | $93.4M | $85.9M | $69.8M | $46.3M |
| PP&E (Net) | $57.2M | $51.5M | $37.5M | $31.2M |
| Operating Leases | $18.5M | $15.6M | $11.2M | $7.2M |
| Other LT Assets | $17.8M | $18.8M | $21.1M | $7.8M |
| Total Assets | $316.2M | $309.9M | $284.2M | $248.0M |
| Current Liabilities | $140.9M | $92.3M | $64.2M | $43.0M |
| Current Leases | $5.8M | $5.9M | $6.2M | $4.6M |
| Deferred Revenue | $7.4M | $574.0K | $316.0K | $384.0K |
| Taxes Payable | — | — | — | $0 |
| Other Current Liab | $108.1M | $84.4M | $57.0M | $37.7M |
| Long-Term Liabilities | $20.3M | $16.1M | $9.9M | $6.1M |
| LT Operating Leases | $20.3M | $16.1M | $9.9M | $6.1M |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $161.2M | $108.4M | $74.1M | $49.1M |
| Shareholders' Equity | $155.0M | $201.5M | $210.1M | $198.9M |
| Paid-In Capital | $21.6M | $26.6M | $33.1M | $40.4M |
| Retained Earnings | $139.9M | $174.6M | $176.8M | $158.3M |
| AOCI | $24.0K | $248.0K | $180.0K | $234.0K |
| Total L&E | $316.2M | $309.9M | $284.2M | $248.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $143.6M | $99.4M | $2.1M | $-18.7M |
| Non-Cash Adjustments | $145.1M | $158.2M | $62.2M | $76.8M |
| Working Capital Changes | $-94.1M | $-110.0M | $-39.8M | $-51.2M |
| Cash from Operations | $194.6M | $147.7M | $24.5M | $6.9M |
| Capital Expenditures | $16.7M | $6.5M | $7.5M | $5.6M |
| Cash from Investing | $-11.4M | $-61.0M | $-26.5M | $-7.9M |
| Share Buybacks | $126.4M | $3.6M | $0 | $0 |
| Dividends Paid | $71.6M | $73.0M | $715.0K | $195.0K |
| Cash from Financing | $-199.6M | $-79.8M | $-1.5M | $-564.0K |
| FX Effect | $-67.0K | $-72.0K | $47.0K | $4.0K |
| Net Change in Cash | $-16.5M | $6.7M | $-3.5M | $-1.6M |
| Beginning Cash | $104.2M | $87.7M | $94.4M | $90.9M |
| Ending Cash | $87.7M | $94.4M | $90.9M | $89.3M |
Frequently Asked Questions
How does MEDIFAST INC make money?
Revenue is driven by a mix of proprietary meal replacement products (Optifast), weight management coaching services, and licensing arrangements with healthcare providers. The financials suggest a significant portion of operating expenses relates to general administration and cost of revenue associated with manufacturing and distributing these health-focused consumables.
What are the main risks for MED?
Significant year-over-year revenue contraction from $1.60B to $385.8M indicates potential market saturation or strategic withdrawal from prior growth initiatives; persistent net losses with a 2025 deficit of $18.7M threaten capital reserves and solvency; high operating expenses relative to declining revenue suggest an inefficient cost structure; heavy reliance on a single core product line makes the company vulnerable to regulatory changes or shifting consumer health trends.
What is MED's competitive advantage?
Strong brand recognition in the clinical nutrition space with a loyal customer base seeking rapid weight loss solutions; established direct-to-consumer distribution channels that reduce reliance on third-party retailers; and proprietary formulations that differentiate products from generic competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.